Similarly, Herbrich and colleagues identified CD200 as a stem cell-specific immunomodulatory target that aids in establishing an immunosuppressive microenvironment by significantly suppressing cytokine secretion in response to AML stem cell activity (67). The gene discussed is CD200; the disease is acute myeloid leukemia.